An international phase II trial including 46 patients with a median age of 7.1 years demonstrated that Triac effectively reduces the high serum T3 concentrations and improved subsequent clinical and biochemical features of thyrotoxicosis, including body weight, heart rate, occurrence of PACs, SHBG and creatinine. The gene discussed is SHBG; the disease is thyrotoxicosis.